Staged mechanical circulatory support in paediatric HIT: Bivalirudin anticoagulation across ECMO, VAD, and cardiac transplantation

IntroductionHeparin induced thrombocytopenia (HIT) with in paediatric population is rare and subsequent anticoagulation management is challenging. Bivalirudin is a viable alternative to heparin for anticoagulating paediatric patients with HIT, though clinical data are limited. We describe the successful management of anticoagulation with bivalirudin from diagnosis through Extracorporeal Membrane Oxygenation (ECMO), Ventricular Assist Device (VAD) implantation, and heart transplantation in a child with dilated cardiomyopathy and HIT.MethodsA 14-year-old girl presented with acute heart failure, intracardiac thrombi, and adenovirus positivity. Heparin was exchanged for bivalirudin once HIT criteria were met, associated with thrombocytopenia and progressive thrombus formation within the right atrium and superior vena cava (SVC). Due to end-organ dysfunction and refractory cardiac failure veno-arterial ECMO was initiated. Failure to achieve sufficient recovery prompted a VAD implantation, and subsequent orthotopic heart transplantation both managed using a modified bivalirudin protocol.ResultsManaging ECMO in the presence of HIT and intracardiac thrombi required careful multidisciplinary planning. We adjusted the bivalirudin infusion from 0.35 to 1.9 mg/kg/hr to maintain an activated Partial Thromboplastin Time (aPTT) of 60-90 s, following our institutional protocol. For VAD implantation, we used citrate for circuit priming and initiated cardiopulmonary bypass without heparin, administering six bivalirudin boluses and escalating the infusion from 1.62 to 10 mg/kg/hr to achieve an Activated Clotting Time (ACT) > 400 s, with continuous ACT monitoring. During transplantation, anticoagulation involved four boluses and increasing the infusion from 0.35 to 5 mg/kg/hr to maintain an ACT >400 s. Despite significant post-CPB coagulopathy, which required delayed chest closure to control bleeding, no thrombotic events occurred. The bivalirudin protocols allowed safe progression through all three phases.ConclusionBivalirudin strategy provided safe, effective antithrombotic management across ECMO, VAD implantation, and heart transplantation in a paediatric patient with HIT. Monitoring its effectiveness at higher anticoagulation levels remains challenging, and patients may require higher doses to achieve desired endpoints.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Staged mechanical circulatory support in paediatric HIT: Bivalirudin anticoagulation across ECMO, VAD, and cardiac transplantation.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Explore how this research connects to clinical practice

More peer-reviewed studies in Drug Development.

• Novel Leech Antimicrobial Peptides — Hirunipins — Kumar et al. (2025)
• Medicinal Leech Genome Assembly — Anticoagulant Gene Catalog — Kvist et al. (2020)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Hirudotherapy in Medicine and Dentistry — Jha K et al. (2015)
• Medicinal leech therapy (hirudotherapy): a brief overview — Singh A (2010)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Investigation of oxidant-antioxidant status in patients treated with hirudotherapy: an experimental study — Sarikan I, Savas H (2024)
• Leech therapeutic applications — Abdualkader A et al. (2013)
• Non-Occlusive Mesenteric Ischemia Due to Hirudotherapy: A Case Report — Akalın Ç, Ekmen N (2020)
• Leech therapy: a history — Hyson J (2005)

Browse all ASH-analysed research →